FN1 and neoplasm: This revealed a reduction of the human CD45+ CD19+ tumor burden in peripheral blood (Supplementary Fig. 20A), a significant increase of fibronectin levels in the BMM of ara-C plus EACA-treated mice (Supplementary Fig. 20B) and survival extension in mice treated with the combination of ara-C plus EACA compared to treatment with ara-C alone (Fig. 8A).